Lower serum cholesterol levels as a risk factor for critical illness polyneuropathy: a matched case-control study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
20
08
2023
accepted:
10
11
2023
medline:
27
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Critical illness polyneuropathy (CIP) is a frequent and underdiagnosed phenomenon among intensive care unit patients. The lipophilic nature of neuronal synapses may result in the association of low serum cholesterol levels with a higher rate of CIP development. We aimed to investigate this issue in critically ill patients. All cases diagnosed with CIP in our tertiary care hospital between 2013 and 2017 were 1:1 matched with controls without the condition by age, sex, and ICD diagnoses. The main risk factors examined were the differences in change between initial and minimum serum total cholesterol levels, and minimum serum total cholesterol levels between matched pairs. Other predictors were serum markers of acute inflammation. We included 67 cases and 67 controls (134 critically ill patients, 49% female, 46% medical). Serum total cholesterol levels decreased more profoundly in cases than controls (median: -74 (IQR -115 to -24) vs. -39 (IQR -82 to -4), median difference: -28, 95% CI [-51, -5]), mg/dl). Minimum serum total cholesterol levels were lower in the cases (median difference: -24, 95% CI [-39, -9], mg/dl). We found significant median differences across matched pairs in maximum serum C-reactive protein (8.9, 95% CI [4.6, 13.2], mg/dl), minimum albumin (-4.2, 95% CI [-6.7, -1.7], g/l), decrease in albumin (-3.9, 95% CI [-7.6, -0.2], g/l), and lowest cholinesterase levels (-0.72, 95% CI [-1.05, -0.39], U/l). Subsequently, more pronounced decreases in serum total cholesterol levels and lower minimum total cholesterol levels during critical care unit hospitalizations may be a risk factor for CIP.
Identifiants
pubmed: 37990042
doi: 10.1038/s41598-023-47232-3
pii: 10.1038/s41598-023-47232-3
pmc: PMC10663605
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20405Subventions
Organisme : Vienna Anniversary Foundation for Higher Education
ID : # H-192221/2019
Informations de copyright
© 2023. The Author(s).
Références
JAMA Netw Open. 2019 May 3;2(5):e194798
pubmed: 31150078
Neural Regen Res. 2014 Jan 1;9(1):101-10
pubmed: 25206749
Mayo Clin Proc. 2013 Nov;88(11):1213-21
pubmed: 24095248
Muscle Nerve. 2005 Aug;32(2):140-63
pubmed: 15825186
Crit Care Med. 2005 Apr;33(4):711-5
pubmed: 15818093
Crit Care Med. 2021 Nov 1;49(11):e1063-e1143
pubmed: 34605781
Drug Saf. 2015 Jun;38(6):519-26
pubmed: 25989944
J Neurochem. 1990 May;54(5):1709-15
pubmed: 2324745
Curr Opin Anaesthesiol. 2015 Apr;28(2):227-36
pubmed: 25590467
Nat Rev Neurol. 2009 Jul;5(7):372-9
pubmed: 19578344
Clin Nutr ESPEN. 2023 Oct;57:311-317
pubmed: 37739674
Neural Regen Res. 2022 Feb;17(2):271-276
pubmed: 34269187
Neurology. 2006 Oct 24;67(8):1421-5
pubmed: 17060568
Nature. 2005 Dec 1;438(7068):612-21
pubmed: 16319881
Intensive Care Med. 2000 Sep;26(9):1360-3
pubmed: 11089765
J Intensive Care Med. 2017 Jun;32(5):346-352
pubmed: 26951579
J Biol Chem. 1997 Dec 5;272(49):30766-73
pubmed: 9388216
Intensive Care Med. 2014 May;40(5):683-90
pubmed: 24623137
Dan Med J. 2012 Oct;59(10):A4511
pubmed: 23158890
J Gen Intern Med. 2015 Mar;30(3):348-58
pubmed: 25575908
Neurohospitalist. 2017 Jan;7(1):41-48
pubmed: 28042370
J Clin Neuromuscul Dis. 2011 Jun;12(4):197-218
pubmed: 22361518
Lancet Neurol. 2011 Oct;10(10):931-41
pubmed: 21939902
Crit Care. 2003 Dec;7(6):413-4
pubmed: 14624677
Eur J Neurol. 2006 Nov;13(11):1203-12
pubmed: 17038033
Crit Care Med. 2009 Oct;37(10 Suppl):S316-20
pubmed: 20046116